thalidomide has been researched along with Cognition Disorders in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current Alzheimer's disease interventions are symptomatic treatments with limited efficacy that do not address etiology." | 1.38 | Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. ( Eslami, P; Gabbita, SP; Greig, NH; Harris-White, ME; Johnson, MF; Kobritz, NK; Sharma, SP; Srivastava, MK; Tweedie, D; Zemlan, FP, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baratz, R | 1 |
| Tweedie, D | 3 |
| Wang, JY | 1 |
| Rubovitch, V | 1 |
| Luo, W | 2 |
| Hoffer, BJ | 1 |
| Greig, NH | 3 |
| Pick, CG | 1 |
| Belarbi, K | 1 |
| Jopson, T | 1 |
| Arellano, C | 1 |
| Rosi, S | 1 |
| Gabbita, SP | 1 |
| Srivastava, MK | 1 |
| Eslami, P | 1 |
| Johnson, MF | 1 |
| Kobritz, NK | 1 |
| Zemlan, FP | 1 |
| Sharma, SP | 1 |
| Harris-White, ME | 1 |
| Corn, BW | 1 |
| Moughan, J | 1 |
| Knisely, JP | 2 |
| Fox, SW | 1 |
| Chakravarti, A | 2 |
| Yung, WK | 1 |
| Curran, WJ | 2 |
| Robins, HI | 2 |
| Brachman, DG | 2 |
| Henderson, RH | 2 |
| Mehta, MP | 2 |
| Movsas, B | 2 |
| Berkey, B | 1 |
| Yung, AW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Trial of Conventional vs IMRT Whole Brain Radiotherapy for Brain Metastases[NCT01890278] | 60 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thalidomide and Cognition Disorders
| Article | Year |
|---|---|
Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Cognition; Cognition D | 2008 |
A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Brain Neoplasms; Cognition Disorders; Combi | 2008 |
3 other studies available for thalidomide and Cognition Disorders
| Article | Year |
|---|---|
Transiently lowering tumor necrosis factor-α synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice.
Topics: Animals; Apoptosis; Brain; Brain Injuries; Cognition Disorders; Disease Models, Animal; Enzyme-Linke | 2015 |
TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation.
Topics: Analysis of Variance; Animals; Apoptosis Regulatory Proteins; Cognition Disorders; Disease Models, A | 2012 |
Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cells, Cultured; Cognition Disorders; Disease Models, Animal; Humans; Ma | 2012 |